Defibrillation Threshold Testing: Current Status.

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• Transvenous implantable cardioverter-defibrillator (ICD) implantation historically included defibrillation threshold (DFT) testing.
• Current practice and guidelines have shifted away from routine DFT testing for transvenous ICDs, except in specific clinical scenarios.
• Risk stratification tools are emerging to aid in the decision-making process for DFT testing.

Purpose of the Study:

• To review the current role and recommendations for defibrillation threshold (DFT) testing in patients receiving implantable cardioverter-defibrillators (ICDs).
• To address the uncertainties surrounding DFT testing for the newer subcutaneous ICD (S-ICD) system.
• To evaluate the implications of current guidelines on DFT testing practices.

Main Methods:

• Literature review of existing guidelines and studies on ICD implantation and DFT testing.
• Analysis of current recommendations from major cardiology societies.
• Discussion of the evolving role of DFT testing in the context of transvenous and subcutaneous ICD technologies.

Main Results:

• DFT testing is no longer universally recommended for transvenous ICD implantation, with risk scores helping to guide its necessity.
• There is limited data and significant uncertainty regarding the role of DFT testing for subcutaneous ICDs.
• Current guidelines maintain a Class I recommendation for performing DFT testing at the time of subcutaneous ICD implantation.

Conclusions:

• The necessity of DFT testing for transvenous ICDs has diminished, but remains relevant in select cases.
• Further research is crucial to establish definitive guidelines for DFT testing in subcutaneous ICD recipients.
• Dismissing the current Class I recommendation for subcutaneous ICD DFT testing requires more robust evidence.